REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
26/12/2025
Voltar para busca
Dado oficial do USPTO
ETHICA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
57
Atualização mais recente
27/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 41, 42
Data de depósito
22/07/2003
Data de registro
26/12/2006
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/02/2017
Última transação
27/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
01/09/2002
Primeiro uso no comércio
01/09/2002
Código do desenho
1
Tipo de titular
03
Localização do titular
KIRKLAND, QUEBEC, CA
Examinador
ANKRAH,NAAKWAMA S
Unidade examinadora
L90
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
ETHICA CRO INC.
Ethica Clinical Research Inc.
Ethica Clinical Research Inc.
Representantes
Dan S. Cohn HUSCH BLACKWELL LLP
Classificação técnica
Classes Nice
Classe 35Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Clinical trial supplies management servicesnamely-customized drug packaging and labelingcentral and site administered randomization and study supply distribution; developing and managing distribution and storage logistics for all clinical suppliesnamely study drugs and devicescase report formsstudy binders and all study related documentation; clinical trial management servicesnamely-pre-study document collection and reviewsite selectionpre-study site visitsinitiation visitsmonitoring visitsclose-out visitsproject tracking and monitoring reportsnegotiation and administration of investigator grantslabelingpackagingdistributioncoordination and tracking of clinical trial materialsregulatory document processingcentral laboratory selection and coordination; managing site and study-specific subject recruitment strategies and programsnamely contingency strategies and solutions to address specific project challenges; managing the development of all study related documents and materialsnamely study protocolsamendmentspaper and electronic case report formsinformed consent forms; managing study operations/monitoring manuals in accordance with data management conventionsweb-based data listingsnamely adverse eventsenrollment statusefficacy endpoints and paper and electronic study newsletters; management of tracking tools for enrollmentessential documentsmonitoringsubject and case report form trackingdrug accountabilitydata queries and adverse events; managing all aspects of study drug reconciliation and inventory and distribution reports; managing all aspects of clinical trialsnamely managing investigatorstechniciansparticipantsethical reviewsinvestigator meetingsdatabasesstatistical analyses and reportingrandomization logisticsmedical writing services; recruitment of investigatorstechnicians and participants; providing strategies for recruitment of participants
Classe 41
Study specific clinical personnel training programs for investigatorscoordinators and investigator meetings; conducting investigator meetings
Classe 42
Research services for clinical trials for othersnamely conducting an ethical review of projects to protect the rights and welfare of research participantsdeveloping study protocolsdesigning case report formsdeveloping participant screening toolsnamely general and medical questionnairesdeveloping complete databases in accordance with strict guidelinestracking of study parametersproviding statistical analysesreporting and developing tracking tools for enrollmentessential documentsmonitoringsubject and case report form trackingdrug accountabilitydata queries and adverse events; developing and implementing randomization logisticsnamely randomization envelopescustomized blind-breakable drug labelingcode break management and reportsmanufacturing of subject-and protocol-specific kits using bulk oral and topical medications; medical writing servicesnamely-drafting clinical study protocolsamendmentscase report formsinformed consent formsstatistical analysis plansfull integrated clinical research reportspublicationsabstracts and manuscript; developing site and study-specific subject recruitment strategies and programsnamely contingency strategies and solutions to address specific project challenges; developing study operations and monitoring manuals in accordance with data management conventionsweb-based data listingsnamely adverse eventsenrollment statusefficacy endpoints and paper and electronic study newsletters
Publicações
Histórico de despachos e eventos da marca no USPTO.
57 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
20/09/2023
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
23/02/2017
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
23/02/2017
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
23/02/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23/02/2017
E89R
TEAS SECTION 8 & 9 RECEIVED
22/12/2016
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
26/12/2015
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
16/01/2013
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
15/01/2013
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/01/2013
E815
TEAS SECTION 8 & 15 RECEIVED
20/12/2012
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
23/11/2009
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
23/11/2009
EXPT
EXPARTE APPEAL TERMINATED
29/01/2007
R.PR
REGISTERED-PRINCIPAL REGISTER
26/12/2006
PUBO
PUBLISHED FOR OPPOSITION
10/10/2006
NPUB
NOTICE OF PUBLICATION
20/09/2006
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
18/08/2006
ALIE
ASSIGNED TO LIE
11/08/2006
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/08/2006
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/07/2006
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/06/2006
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/06/2006
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
15/05/2006
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
15/05/2006
GECD
ACTION DENYING REQ FOR RECON E-MAILED
15/02/2006
CNCF
ACTION CONTINUING FINAL - COMPLETED
15/02/2006
EXPI
EX PARTE APPEAL-INSTITUTED
28/12/2005
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
28/12/2005
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
22/12/2005
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2005
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/12/2005
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/12/2005
GNFR
FINAL REFUSAL E-MAILED
13/06/2005
CNFR
FINAL REFUSAL WRITTEN
13/06/2005
IUAA
USE AMENDMENT ACCEPTED
20/05/2005
ACEC
AMENDMENT FROM APPLICANT ENTERED
18/05/2005
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/04/2005
FAXX
FAX RECEIVED
29/04/2005
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/04/2005
CNSI
SUSPENSION INQUIRY WRITTEN
11/04/2005
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/03/2005
GNSL
LETTER OF SUSPENSION E-MAILED
09/09/2004
CNSL
SUSPENSION LETTER WRITTEN
09/09/2004
ACEC
AMENDMENT FROM APPLICANT ENTERED
12/08/2004
ALIE
ASSIGNED TO LIE
12/08/2004
ACEC
AMENDMENT FROM APPLICANT ENTERED
09/08/2004
ALIE
ASSIGNED TO LIE
09/08/2004
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/07/2004
PAPER RECEIVED
30/07/2004
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/07/2004
GNRT
NON-FINAL ACTION E-MAILED
27/01/2004
DOCK
ASSIGNED TO EXAMINER
12/01/2004
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
17/09/2003
IUAF
USE AMENDMENT FILED
10/09/2003
EAAU
TEAS AMENDMENT OF USE RECEIVED
10/09/2003
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ETHICA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.